MX2021009383A - Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. - Google Patents
Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.Info
- Publication number
- MX2021009383A MX2021009383A MX2021009383A MX2021009383A MX2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A MX 2021009383 A MX2021009383 A MX 2021009383A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lysosomal storage
- storage diseases
- disorders associated
- treating symptoms
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000015439 Lysosomal storage disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 title abstract 2
- 206010056696 Gaze palsy Diseases 0.000 abstract 2
- 206010017577 Gait disturbance Diseases 0.000 abstract 1
- 208000015872 Gaucher disease Diseases 0.000 abstract 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 abstract 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 238000002641 enzyme replacement therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- -1 quinuclidine compound Chemical class 0.000 abstract 1
- 150000008584 quinuclidines Chemical class 0.000 abstract 1
- 230000001711 saccadic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción se refiere a métodos para tratar o prevenir particulares síntomas y trastornos que se asocian con enfermedades del almacenamiento lisosómico utilizando compuestos de quinuclidina de la fórmula (I), opcionalmente combinados con terapia de reemplazo enzimático. Esto incluye parálisis de la mirada supranuclear, incluyendo parálisis de la mirada sacádica horizontal y vertical, y deficiencias cognitivas o trastornos de la marcha, tales como en un paciente que tenga enfermedad de Gaucher o enfermedad de Niemann-Pick tipo C. También se describe una composición farmacéutica que comprende un compuesto de quinuclidina para su uso en dichos métodos.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800996P | 2019-02-04 | 2019-02-04 | |
| US201962851433P | 2019-05-22 | 2019-05-22 | |
| US201962894167P | 2019-08-30 | 2019-08-30 | |
| US201962937618P | 2019-11-19 | 2019-11-19 | |
| US202062962647P | 2020-01-17 | 2020-01-17 | |
| PCT/US2020/016441 WO2020163245A1 (en) | 2019-02-04 | 2020-02-03 | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009383A true MX2021009383A (es) | 2021-09-10 |
Family
ID=69743942
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009384A MX2021009384A (es) | 2019-02-04 | 2020-02-03 | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. |
| MX2021009383A MX2021009383A (es) | 2019-02-04 | 2020-02-03 | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009384A MX2021009384A (es) | 2019-02-04 | 2020-02-03 | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220016092A1 (es) |
| EP (2) | EP3920913A1 (es) |
| JP (2) | JP2022520747A (es) |
| KR (2) | KR20210123353A (es) |
| CN (2) | CN113645969A (es) |
| AU (2) | AU2020218496A1 (es) |
| BR (2) | BR112021015099A2 (es) |
| CA (2) | CA3128039A1 (es) |
| IL (3) | IL313808A (es) |
| MX (2) | MX2021009384A (es) |
| SG (2) | SG11202107842QA (es) |
| TW (2) | TW202045168A (es) |
| WO (2) | WO2020163245A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| IL295255A (en) | 2020-02-03 | 2022-10-01 | Genzyme Corp | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| CA3186766A1 (en) | 2020-07-24 | 2022-01-27 | Danielle Combessis | Pharmaceutical compositions comprising venglustat |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (es) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| RU2645675C2 (ru) | 2011-03-18 | 2018-02-27 | Джензим Корпорейшн | Ингибиторы глюкозилцерамид-синтазы |
| WO2015089067A1 (en) | 2013-12-11 | 2015-06-18 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
-
2020
- 2020-02-03 KR KR1020217027946A patent/KR20210123353A/ko active Search and Examination
- 2020-02-03 JP JP2021545375A patent/JP2022520747A/ja active Pending
- 2020-02-03 SG SG11202107842QA patent/SG11202107842QA/en unknown
- 2020-02-03 EP EP20709405.3A patent/EP3920913A1/en active Pending
- 2020-02-03 CA CA3128039A patent/CA3128039A1/en active Pending
- 2020-02-03 WO PCT/US2020/016441 patent/WO2020163245A1/en unknown
- 2020-02-03 CN CN202080025346.0A patent/CN113645969A/zh active Pending
- 2020-02-03 CN CN202080025266.5A patent/CN113710249A/zh active Pending
- 2020-02-03 MX MX2021009384A patent/MX2021009384A/es unknown
- 2020-02-03 IL IL313808A patent/IL313808A/en unknown
- 2020-02-03 US US17/428,505 patent/US20220016092A1/en active Pending
- 2020-02-03 EP EP20709406.1A patent/EP3920914A1/en active Pending
- 2020-02-03 AU AU2020218496A patent/AU2020218496A1/en active Pending
- 2020-02-03 SG SG11202107844UA patent/SG11202107844UA/en unknown
- 2020-02-03 MX MX2021009383A patent/MX2021009383A/es unknown
- 2020-02-03 AU AU2020217659A patent/AU2020217659A1/en active Pending
- 2020-02-03 US US17/428,504 patent/US20220023273A1/en active Pending
- 2020-02-03 JP JP2021545383A patent/JP7511567B2/ja active Active
- 2020-02-03 BR BR112021015099-4A patent/BR112021015099A2/pt unknown
- 2020-02-03 WO PCT/US2020/016440 patent/WO2020163244A1/en unknown
- 2020-02-03 BR BR112021015172-9A patent/BR112021015172A2/pt unknown
- 2020-02-03 CA CA3128041A patent/CA3128041A1/en active Pending
- 2020-02-03 KR KR1020217027945A patent/KR20210123352A/ko active Search and Examination
- 2020-02-04 TW TW109103398A patent/TW202045168A/zh unknown
- 2020-02-04 TW TW109103397A patent/TW202045167A/zh unknown
-
2021
- 2021-07-28 IL IL285187A patent/IL285187A/en unknown
- 2021-08-02 IL IL285304A patent/IL285304A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113645969A (zh) | 2021-11-12 |
| AU2020218496A1 (en) | 2021-08-26 |
| SG11202107842QA (en) | 2021-08-30 |
| BR112021015172A2 (pt) | 2021-09-28 |
| TW202045167A (zh) | 2020-12-16 |
| JP7511567B2 (ja) | 2024-07-05 |
| MX2021009384A (es) | 2021-09-10 |
| KR20210123352A (ko) | 2021-10-13 |
| TW202045168A (zh) | 2020-12-16 |
| US20220016092A1 (en) | 2022-01-20 |
| AU2020217659A1 (en) | 2021-08-26 |
| BR112021015099A2 (pt) | 2021-10-05 |
| KR20210123353A (ko) | 2021-10-13 |
| EP3920913A1 (en) | 2021-12-15 |
| US20220023273A1 (en) | 2022-01-27 |
| CA3128039A1 (en) | 2020-08-13 |
| WO2020163245A1 (en) | 2020-08-13 |
| IL285304A (en) | 2021-09-30 |
| EP3920914A1 (en) | 2021-12-15 |
| WO2020163244A1 (en) | 2020-08-13 |
| SG11202107844UA (en) | 2021-08-30 |
| IL285187A (en) | 2021-09-30 |
| JP2022519274A (ja) | 2022-03-22 |
| CN113710249A (zh) | 2021-11-26 |
| JP2022520747A (ja) | 2022-04-01 |
| CA3128041A1 (en) | 2020-08-13 |
| IL313808A (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009383A (es) | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. | |
| BR112013031510A2 (pt) | [1,3]oxazinas | |
| EA201290519A1 (ru) | Положительные аллостерические модуляторы рецептора хинолин амида m1 | |
| MX2012001985A (es) | Derivados de 3-amino-5-fenil-5,6-dihidro-2h-[1,4]oxazina. | |
| TN2011000437A1 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| MX344308B (es) | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. | |
| MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
| NI201100100A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1. | |
| EA201200686A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера | |
| MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
| ME01836B (me) | Postupci upotrebe sastava aminopiridina s odloženim oslobađanjem | |
| MX2012002449A (es) | Terapia de reemplazo de enzimas con aumento escalonado de la dosis para tratar la deficiencia de esfingomielinasa acida. | |
| NZ602777A (en) | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | |
| BR112012031337A2 (pt) | derivados de 5-amino-3,6-di-hidro-1h-pirazin-2-ona úteis como inibidores de beta-secretase (bace) | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| MX2021007592A (es) | Compuestos macrociclicos y su uso en el tratamiento de enfermedades. | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| UA96447C2 (ru) | Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы | |
| BR112013021798A2 (pt) | 1,4 tiazepinaas/sulfonas como inibidores de bace1 e/ou bace2 | |
| BR112016015763B8 (pt) | preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma | |
| MX2012010657A (es) | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. | |
| BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
| MX2022000083A (es) | Inhibidores de monoacilglicerol lipasa (magl) heterociclicos. |